Biodesix (BDSX) Operating Expenses (2019 - 2026)

Biodesix has reported Operating Expenses for 8 years, with the latest figure at $31.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 17.21% year-over-year to $31.8 million; the trailing twelve-month figure through Mar 2026 stood at $92.2 million (down 40.59% YoY), and the FY2025 full-year result was $6.7 million, down 93.69% from the prior year.
• Operating Expenses for Q1 2026 stood at $31.8 million, up from $1.9 million in the prior quarter.
• The five-year high for Operating Expenses was $100.6 million in Q4 2024, with the low at $1.4 million in Q3 2024.
• Historically, Operating Expenses has averaged $25.2 million across 5 years, with a median of $22.8 million in 2023.
• The largest YoY upside for Operating Expenses was 1942.45% in 2025 against a maximum downside of 98.08% in 2025.
• Biodesix's Operating Expenses stood at $23.5 million in 2022, then dropped by 8.34% to $21.5 million in 2023, then jumped by 367.13% to $100.6 million in 2024, then sank by 98.08% to $1.9 million in 2025, then soared by 1543.69% to $31.8 million in 2026.
• The last three Operating Expenses figures came in at $31.8 million (Q1 2026), $1.9 million (Q4 2025), and $28.8 million (Q3 2025), per Business Quant data.